top of page
Blog: Blog2
GPCR News
Search
Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment ...
April 2022 Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment Of Schizophrenia & Other...

GPCR News
Apr 1, 20221 min read
0
0
Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical ...
April 2022 Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical Study "Geneva, Switzerland,...

GPCR News
Apr 1, 20221 min read
1
0
ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships
March 2022 "February 17, 2022 08:00 AM Eastern Standard Time SAN FRANCISCO & SHANGHAI- ShouTi Inc., a clinical-stage global...

GPCR News
Mar 1, 20221 min read
12
0
Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment ...
March 2022 Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment Of Neuropathic Pain "—...

GPCR News
Mar 1, 20221 min read
1
0
Addex Therapeutics To Release Full-Year 2021 Financial Results And Host Conference Call On March 10
March 2022 "Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company...

GPCR News
Mar 1, 20221 min read
3
0
Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B ...
March 2022 Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B Clinical Trial "MONTREAL (CANADA) –...

GPCR News
Mar 1, 20221 min read
2
0
Exscientia welcomes Richard J. Law, as their new Chief Business Officer
March 2022 "Congratulations to Richard J. Law, our newly named Chief Business Officer. Richard is the architect behind nearly all of...

GPCR News
Mar 1, 20221 min read
1
0
Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology
March 2022 "Explicyte grants Domain Therapeutics exclusivity on data related to GPCR implicated in immunoresistance, to develop first-in...

GPCR News
Mar 1, 20221 min read
2
0
Research Network on Signal Transduction (ERNEST) has established an Emergency Fund for Ukrainian ...
March 2022 ERNEST has established an Emergency Fund for Ukrainian researchers. "General Eligibility Researchers affiliated to any legal...

GPCR News
Mar 1, 20221 min read
1
0


Naggie and Rajagopal Elected Members of American Society for Clinical Investigation
March 2022 "March 3, 2022 Susanna Naggie, MD, and Sudarshan Rajagopal, MD, PhD Two School of Medicine faculty members — Susanna Naggie,...

GPCR News
Mar 1, 20221 min read
7
0
Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief ...
March 2022 Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief Commercial Officer "SAN DIEGO –...

GPCR News
Mar 1, 20221 min read
0
0


Dr. Marta Filizola - Dr. GPCR Podcast
Next on the Dr. GPCR Podcast, we have none other than Dr. Marta Filizola! Subscribe to the podcast today and get notified when new...

Dr. GPCR News
Feb 10, 20221 min read
31
0
Ermium Therapeutics has constituted its SAB
February 2022 "Ermium Therapeutics Announces the Formation of a Scientific Advisory Board comprising international leaders in GPCRs...

GPCR News
Feb 1, 20221 min read
4
0
AELIS PHARMA launches their IPO for €25 million
February 2022 "We are proud to announce the success of our IPO! Thank you to our shareholders, both historical and new, for their trust....

GPCR News
Feb 1, 20221 min read
2
0
InterAx Biotech AG and Boehringer Ingelheim take collaborate to unlock orphan targets leveraging ...
February 2022 "InterAx Biotech AG and Boehringer Ingelheim take first steps towards collaborating to unlock orphan targets leveraging...

GPCR News
Feb 1, 20221 min read
2
0
Trevena Announce Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu ...
February 2022 Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical...

GPCR News
Feb 1, 20221 min read
6
0
Carola Weiss joins InterAx Biotech AG as VP Business Development
February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined the company as VP Business...

GPCR News
Feb 1, 20221 min read
1
0
Sosei Heptares reported its FY2021 financial result and provided an update on operational activities
February 2022 Read more at the source #DrGPCR #GPCR #IndustryNews

GPCR News
Feb 1, 20221 min read
2
0
Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with ...
February 2022 Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with pioneer as co-founder "Jan 27,...

GPCR News
Feb 1, 20221 min read
8
0


Dr. Juan José Fung - Dr. GPCR Podcast
Mark your calendars! The Dr. GPCR Podcast is back this week with a brand new episode. Our guest is none other than Dr. Juan Jose Fung,...

Dr. GPCR News
Jan 21, 20221 min read
9
0


Mark Schmeizl - Dr. GPCR Podcast
Episode 55 of the Dr. GPCR podcast is now available! Our guest is Mark Schmeizl! He is a pro at Matchmaking the top talent in the life...

Dr. GPCR News
Jan 6, 20221 min read
12
0
Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline ...
January 2022 Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered...

GPCR News
Jan 1, 20221 min read
5
0
Addex Therapeutics CEO Tim Dyer: There is a $4-bil market opportunity in dyskinesia
January 2022 "Watch our CEO Tim Dyer on AlphaStreet. In his interview, Mr. Dyer provides an overview of our #allostericmodulator...

GPCR News
Jan 1, 20221 min read
8
0
Novo Nordisk moves to strengthen obesity efforts
January 2022 "After securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position in the obesity space through a...

GPCR News
Jan 1, 20221 min read
3
0
bottom of page